← Home
Merck
-4.8%
Pharma / Pharma
Press Releases
| Date | Press release |
|---|---|
| 2025-04-29 06:45:00 | Merck Breaks Ground On New $1 Billion Biologics Center Of Excellence In Wilmington, Delaware Rahway, n.j.--(business wire)--merck breaks ground on new $1 billion biologics center of excellence in wilmington, delaware. |
| 2025-04-28 02:13:00 | Merck Kgaa, Darmstadt, Germany To Acquire Springworks Therapeutics To Accelerate Sustainable Growth Of Healthcare Business – purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – planned acquisition will immediately add revenue and accelerate mid- to long-term growth for merck kgaa, darmstadt, germany’s healthcare business – – springworks therapeutics is a u.s. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas – – planned acquisition will strengthen the presence of merck kgaa, darmstadt, germany’s healthcare business in the united states and expand reach of springworks’ therapeutic innovations to more patients with rare tumors worldwide – stamford, conn., april 28, 2025 (globe newswire) -- merck kgaa, darmstadt, germany (dax: mrk), a leading science and technology company, and springworks therapeutics, inc. (nasdaq: swtx), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the companies have entered into a definitive agreement for merck kgaa, darmstadt, germany to acquire springworks. |
| 2025-04-28 02:11:00 | Merck Kgaa, Darmstadt, Germany, To Acquire Us Biopharma Company Springworks Therapeutics To Accelerate Sustainable Growth Of Healthcare Business Darmstadt, germany--(business wire)--merck kgaa, darmstadt, germany (dax: mrk), a leading science and technology company, and springworks therapeutics, inc. (nasdaq: swtx), a stamford, connecticut-based commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the companies have entered into a definitive agreement for merck kgaa, darmstadt, germany, to acquire springworks. the purchase price of $47 per share in cash represents an equity value of appr. |
| 2025-04-27 12:00:00 | Keytruda® (pembrolizumab) As Perioperative Treatment With Standard Of Care (soc) Adjuvant Therapy Significantly Improved Event-free Survival Compared To Soc Alone In Patients With Resectable Locally Advanced Head And Neck Squamous Cell Carcinoma Rahway, n.j.--(business wire)---- $mrk #mrk--merck (nyse: mrk), known as msd outside of the united states and canada, today announced results from the phase 3 keynote-689 trial evaluating keytruda® (pembrolizumab), merck’s anti-pd-1 therapy, as a perioperative treatment regimen for patients with stage iii or iva, resected, locally advanced head and neck squamous cell carcinoma (la-hnscc). results at the first interim analysis of the trial showed keytruda significantly improved event-free survival (efs) as pa. |
| 2025-04-24 06:30:00 | Merck Announces First-quarter 2025 Financial Results Rahway, n.j.--(business wire)--merck announces first-quarter 2025 financial results. |
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Legal